The Spotlight Falls on India
Applied Clinical Trials
Indian CROs face new guidelines as the country's clinical trial market continues to face infrastructure issues.
Clinical research in India has again come under scrutiny. A comprehensive new market report has highlighted the pros and cons of organizing trials in India, and in the wake of a case of suspected fraud, the regulators have issued new guidelines for CROs.
Number of Phase III Trials Started in 2008
Inside the country
India is a very attractive cost-value proposition, but tax incentives are lacking and infrastructure weaknesses continue to be a problem, according to the authors of "Taking Wings: Coming of Age of the Indian Pharmaceutical Outsourcing Industry," published by Ernst & Young and the Organisation of Pharmaceutical Producers of India.
Strong growth has occurred in recent years, particularly in Phase II and III clinical trials (see chart). The fiscal constraints on global pharmaceutical and biotech companies have contributed to this growth, along with the Indian government's commitment to support the life sciences sector. The Indian population's strong technical drug chemistry skills, as well as the responsiveness of sites, have also helped. Data protection and exclusivity are still major areas of concern, however.
"There are no provisions in Indian laws regarding whether the data collected from clinical trials can be used by the Drug Controller General of India in its approval procedures for other drugs," the authors note. "In addition, there is a debate about whether data exclusivity laws need to be enacted in India."
You can download the report free-of-charge at www.indiaoppi.com
Meanwhile, the New Delhi-based regulatory authority, the Central Drugs Standard Control Organization (CDSCO), has issued draft guidelines that require the registration of CROs that conduct human studies on drugs, cosmetics, and medical devices. Under the guidelines, CROs must adhere to SOPs to obtain a license of registration, which is valid for five years. CDSCO is currently seeking feedback on the proposed changes.
"This is an attempt by the government to control scientific and ethical standards for clinical trials in India," said Nermeen Varawalla, MD, MBA, president and chief executive officer of ECCRO (Emerging Country Contract Research Organisation). "It reflects the government's keenness to promote the sector and the realization that highest standards are critical for the sector to thrive. Hence, they are a good thing and a significant statement to the international community, although in themselves, the impact of these rules will be less significant."
Also in India, suspected fraud has prompted Glenmark Pharmaceuticals to close its clinical trial site at Guru Gobind Hospital, Jamnagar, Gujarat. At the site, Omnicare Clinical Research was conducting a Phase IIb study for Glenmark's chronic obstructive pulmonary disease/asthma product, Oglemilast.
During monitoring activities immediately after initiation of the site in late 2008, Omnicare suspected fraudulent activity, and the clinical investigator, A. Bhattacharya, MD, has now been suspended.—Philip Ward
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
